Eltrombopag
12.5 mg · Tablet
- Prescription only
- Thrombopoietin Receptor Agonist
- Active substance
- Eltrombopag
- Made by
- Zydus Lifesciences Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (ELTROMBOPAG). It describes the substance, not this exact product.
Eltrombopag is a TPO-receptor agonist that interacts with the transmembrane domain of the human TPO-receptor (also known as cMpl) and initiates signaling cascades that induce proliferation and differentiation of megakaryocytes leading to increased platelet production.
Absorbed eltrombopag is extensively metabolized, predominantly through pathways, including cleavage, oxidation and conjugation with glucuronic acid, glutathione or cysteine.
Effect of Food A standard high-fat breakfast (876 calories, 52 g fat, 71 g carbohydrate, 34 g protein and 427 mg calcium) significantly decreased plasma eltrombopag AUC 0-INF by approximately 59% and C max by 65% and delayed T max by 1 hour.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-21
Safety of the active substance
From the US prescribing label for the same active substance (ELTROMBOPAG). It describes the substance, not this exact product.
WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C and RISK OF HEPATOTOXICITY In patients with chronic hepatitis C, eltrombopag in combination with interferon and ribavirin may increase the risk of hepatic decompensation [see Warnings and Precautions ( 5.1 )].
The most common serious adverse reaction and most hemorrhagic reactions followed discontinuation of eltrombopag.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
BulgariaNo exact match for this strength and form
European UnionNo exact match for this strength and form
Details
| Made by | Zydus Lifesciences Limited |
|---|---|
| Active substance | Eltrombopag |
| Strength | 12.5 mg |
| Form | Tablet |
| Route | Oral |
| Packs | 30 TABLET in 1 BOTTLE |
| NDC | 70771-1925 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
34 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Tablet, Film Coated20 products
- Tablet12 products
12.5 mg3
12.5 mg · 3 companies
- Hikma Pharmaceuticals USA Inc.
- Zydus Lifesciences Limited · this page
- Zydus Pharmaceuticals USA Inc.
25 mg3
50 mg3
75 mg3
- Powder, for Suspension2 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.